Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Denufosol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 known ✓ | P41231 | 19/20 | 1.00 |
| ▸ | P2RY4 | P51582 | 12/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Denufosol SCHEMBL15108954 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL22127329 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL30480354 | 1.00 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL561652 | 0.99 | P2RY2 (0.98) | P2RY2P2RY4P2RY6 | |
| Cytarabine 5'-Phosphate SCHEMBL25290865 | 0.94 | P2RY2 (0.89) | P2RY2P2RY4P2RY6 | |
| SCHEMBL29798782 | 0.93 | P2RY2 (0.86) | P2RY2P2RY4P2RY6 | |
| SCHEMBL30111010 | 0.93 | P2RY2 (0.86) | P2RY2P2RY4P2RY6 | |
| SCHEMBL15082664 | 0.91 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL29366605 | 0.89 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Uridine Triphosphate SCHEMBL25298912 | 0.89 | P2RY2 (0.92) | P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576051-B2 | Methods and composition for treating respiratory obstructive diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-17 | — | — | US | claimed |
| US-20250281610-A1 | P2RY2 ACTIVITY MODULATORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-09-11 | — | — | US | claimed |
| EP-4514353-A1 | P2RY2 ACTIVITY MODULATORS | Deutsches Krebsforschungszentrum (DE) | 2025-03-05 | — | — | EP | claimed |
| WO-2023209183-A1 | P2RY2 ACTIVITY MODULATORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-11-02 | — | — | WO | claimed |
| US-20230302031-A1 | Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress Syndrome | INSTITUT GUSTAVE-ROUSSY (FR) | 2023-09-28 | — | — | US | claimed |
| EP-4240339-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | Fred Hutchinson Cancer Center (US) | 2023-09-13 | — | — | EP | claimed |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER CENTER (US) | 2023-08-24 | — | — | US | claimed |
| EP-4157288-A2 | MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROM | Institut Gustave-Roussy (FR) | 2023-04-05 | — | — | EP | claimed |
| US-20220257567-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS DISEASE-19 | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-08-18 | — | — | US | claimed |
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | claimed |
| WO-2022098776-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-12 | — | — | WO | claimed |
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| US-12637414-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-12630498-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630521-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220047818-A1 | AEROSOL DELIVERY DEVICE AND METHOD OF OPERATING THE AEROSOL DELIVERY DEVICE | PARI PHARMA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | P2RY2 8/4885P2RY4 13/4885P2RY6 19/4885 |
| US-12637414-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, ABCC1 | P2RY2 673/4885P2RY4 841/4885P2RY6 386/4885 |
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | P2RY2 1276/4885P2RY4 2287/4885P2RY6 1575/4885 |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | BMP4, P2RY2, GPR39 | P2RY2 2/4885P2RY4 13/4885P2RY6 21/4885 |
| US-12630521-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | P2RY2 421/4885P2RY4 869/4885P2RY6 303/4885 |
| US-12576051-B2 | Methods and composition for treating respiratory obstructive diseases | CFTR, CCR10, SLC26A4 | P2RY2 985/4885P2RY4 1649/4885P2RY6 1214/4885 |
| US-12630498-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | P2RY2 691/4885P2RY4 949/4885P2RY6 376/4885 |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | P2RY2 1869/4885P2RY4 1602/4885P2RY6 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.